SOT101 Shows Clinical Benefit in Patients with ... - Pipelinereview
Nov 12, 2021 · A SOT101 monotherapy arm of the study demonstrated encouraging efficacy signals in the 30 patients with advanced/metastatic solid tumors, including in CPI refractory patients. To date, there has been one confirmed clinical and radiological response and confirmed stable disease in four patients. Additionally, one patient had a partial response ...
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766
Jan 25, 2022 · The Phase 1, randomized, double-blind, placebo-controlled trial will assess the safety, tolerability and pharmacokinetics of escalating single and multiple doses of CVN766 in healthy subjects. The company expects to complete the Phase 1 study by year-end. Cerevance is continuing to actively enroll patients in the Phase 1 study.
All news - Pipelinereview
Nov 6, 2024 · Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody OAKLAND, CA, USA and NANJING, China I November 7, 2024 I Aditum Bio and Leads Biolabs today announced the formation of Oblenio Bio, which is being formed in conjunction with an exclusive option and license agreement to develop LBL-051, […]
Horizon Therapeutics plc Announces First Subject Dosed in Phase …
DUBLIN, Ireland I December 08, 2022 I Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first subject has been dosed in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457, previously known as ARO-XDH. HZN-457 is a small interfering RNA (siRNA) candidate designed to treat ...
Chengdu Origen and Vanotech Announce First Patient
Nov 21, 2023 · Clinical trial of KH631 evaluates single administration gene-therapy treatment for wet AMD. CHENGDU, China and ROCKAWAY, NJ, USA I November 20, 2023 I Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today the first patient dosed in the VAN-2201 multi-center Phase 1 clinical trial evaluating treatment with KH631 for patients with wet ...
PipelineReview.com. Biopharmaceutical News & Clinical Trials
Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing. PD-1 Agonists Pipeline Review. For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin.
Curie Therapeutics Raises $75 Million Financing to Further its …
Dec 2, 2021 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Meissa Announces First Dosing in Phase 2 Study of Intranasal Live ...
Jan 21, 2021 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Sirius Therapeutics Announces Submission to Begin First Clinical …
Nov 10, 2023 · SAN DIEGO, CA, USA & SHANGHAI, China I November 09, 2023 I Sirius Therapeutics today announced it has submitted an application in Australia to begin a first-in-human clinical trial of SRSD107, its next generation siRNA therapeutic for the prevention and treatment of thromboembolic disorders.SRSD107, which specifically targeting coagulation factor XI (FXI), is the first Sirius-developed ...
PD-1 Agonists: a pipeline review of an emerging class of novel …
BARCELONA, Spain I October 2, 2023 I La Merie Publishing released its newest product reviewing the pipeline of PD-1 agonist antibody therapy candidates in R&D:. PD-1 Agonists Pipeline Review. Target: PD-1 (programmed cell death protein-1)Product Category: Antibody This product provides basic information on antibody therapy candidates in …